BAVA: Travel Health growth lifted nine-month results, 2026 guidance unchanged
BAVA lifted nine-month revenue 2.2% on Travel Health growth, posted a 34.9% EBITDA margin and held its 2026 guidance steady, per TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
BAVA's revenue for the first nine months rose 2.2%, with Travel Health as the main driver, according to TradingView. The EBITDA margin for the period came in at 34.9%.
The company kept its 2026 guidance unchanged, targeting revenue of DKK 6,100 million and an EBITDA margin of 32%.
The source notes that its text is an AI-generated summary that may contain inaccuracies, so key figures should be checked against the original filing.
why it matters
For investors, the key point is that growth came from one business line while the forecast was not revised, so expectations for revenue and margin remain as they were. The report shows how the company is tracking against its full-year plan.
market impact
BAVA: revenue growth and unchanged guidance support interest in the stock
tags
instruments
sources
- BAVA: Travel Health growth drove 9M results as 2026 guidance held steady — TradingView, 13 November 2026 at 12:57 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗